Microbix Biosystems (TSE:MBX) Director Purchases C$23,000.00 in Stock

Microbix Biosystems Inc. (TSE:MBX) Director Martin Marino bought 100,000 shares of the business’s stock in a transaction dated Monday, December 22nd. The shares were bought at an average price of C$0.23 per share, with a total value of C$23,000.00. Following the completion of the transaction, the director owned 1,691,667 shares in the company, valued at approximately C$389,083.41. This trade represents a 6.28% increase in their position.

Martin Marino also recently made the following trade(s):

• On Monday, December 29th, Martin Marino purchased 52,500 shares of Microbix Biosystems stock. The stock was bought at an average price of C$0.24 per share, for a total transaction of C$12,600.00.

Microbix Biosystems Price Performance

MBX stock traded up C$0.01 during midday trading on Friday, reaching C$0.22. The company had a trading volume of 35,000 shares, compared to its average volume of 107,382. Microbix Biosystems Inc. has a 1-year low of C$0.21 and a 1-year high of C$0.55. The stock has a 50 day moving average price of C$0.24 and a 200-day moving average price of C$0.25. The company has a debt-to-equity ratio of 22.61, a current ratio of 7.15 and a quick ratio of 5.57. The company has a market capitalization of C$30.54 million, a price-to-earnings ratio of -13.75 and a beta of 0.03.

Microbix Biosystems (TSE:MBX) last released its earnings results on Thursday, December 18th. The company reported C($0.01) EPS for the quarter. The firm had revenue of C$3.74 million during the quarter. Microbix Biosystems had a net margin of 13.86% and a return on equity of 12.65%. Equities research analysts expect that Microbix Biosystems Inc. will post 0.02 earnings per share for the current year.

Microbix Biosystems Company Profile

Microbix develops proprietary biological technology solutions for human health and well-being, with about 90 skilled employees and sales growing from a base of over $1 million per month. It makes a wide range of critical biological materials for the global diagnostics industry, notably antigens for immunoassays and its laboratory quality assessment products that support clinical lab proficiency testing, assay development and validation, or clinical lab workflows.